Should I buy or sell Aadi Bioscience stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aadi Bioscience in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AADI shares. View AADI analyst ratings or view top-rated stocks .

What is Aadi Bioscience's stock price target for 2024?

2 equities research analysts have issued 1 year target prices for Aadi Bioscience's shares. Their AADI share price targets range from $5.00 to $36.00. On average, they expect the company's stock price to reach $24.67 in the next year. This suggests a possible upside of 1,255.3% from the stock's current price. View analysts price targets for AADI or view top-rated stocks among Wall Street analysts .

How have AADI shares performed in 2024?

Aadi Bioscience's stock was trading at $2.02 at the start of the year. Since then, AADI shares have decreased by 9.9% and is now trading at $1.82. View the best growth stocks for 2024 here .

Are investors shorting Aadi Bioscience?

Aadi Bioscience saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 943,100 shares, a decline of 16.5% from the March 15th total of 1,130,000 shares. Based on an average trading volume of 386,100 shares, the short-interest ratio is currently 2.4 days. Currently, 5.4% of the company's stock are short sold. View Aadi Bioscience's Short Interest .

When is Aadi Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our AADI earnings forecast .

How were Aadi Bioscience's earnings last quarter?

Aadi Bioscience, Inc. (NASDAQ:AADI) issued its earnings results on Wednesday, March, 13th. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.67) by $0.07. The company had revenue of $6.33 million for the quarter, compared to analyst estimates of $6.46 million. Aadi Bioscience had a negative trailing twelve-month return on equity of 52.53% and a negative net margin of 270.04%.

When did Aadi Bioscience's stock split?

Aadi Bioscience's stock reverse split on the morning of Friday, August 27th 2021. The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Aadi Bioscience?

Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AADI

Aadi Bioscience (AADI) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free AADI Stock Alerts

$1.82

+0.03 (+1.68%)

(As of 04/17/2024 ET)

Compare

Today's Range: $1.75
▼
$1.83
50-Day Range: $1.77
▼
$2.44
52-Week Range: $1.55
▼
$8.65

Volume: 200,707 shs
Average Volume: 379,071 shs
Market Capitalization: $44.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $24.67

Get Aadi Bioscience alerts:

Aadi Bioscience MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 1,255.3% Upside
$24.67 Price Target
Short Interest: Healthy
5.41% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.82
Based on 2 Articles This Week
Insider Trading: Selling Shares
$198,819 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.47) to ($2.91) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.80 out of 5 stars

Medical Sector

370th out of 913 stocks

Pharmaceutical Preparations Industry

152nd out of 396 stocks

3.3

Analyst's Opinion

Consensus Rating
Aadi Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Aadi Bioscience has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
5.41% of the float of Aadi Bioscience has been sold short.
Short Interest Ratio / Days to Cover
Aadi Bioscience has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aadi Bioscience has recently decreased by 16.54%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Aadi Bioscience does not currently pay a dividend.
Dividend Growth
Aadi Bioscience does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AADI.

2.1

News and Social Media Coverage

News Sentiment
Aadi Bioscience has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Aadi Bioscience this week, compared to 2 articles on an average week.
Search Interest
Only 8 people have searched for AADI on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Aadi Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aadi Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $198,819.00 in company stock.
Percentage Held by Insiders
35.80% of the stock of Aadi Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
52.08% of the stock of Aadi Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Aadi Bioscience are expected to decrease in the coming year, from ($2.47) to ($2.91) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aadi Bioscience is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aadi Bioscience is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aadi Bioscience has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Aadi Bioscience Stock (NASDAQ:AADI)

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

AADI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AADI Stock News Headlines

April 4, 2024 | insidertrades.com

Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Neil Desai Sells 17,772 Shares

April 14, 2024 | americanbankingnews.com

Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Declines By 16.5%

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 13, 2024 | americanbankingnews.com

Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Significant Decrease in Short Interest

April 9, 2024 | finance.yahoo.com

Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting

April 9, 2024 | prnewswire.com

Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting

March 17, 2024 | prnewswire.com

Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)

March 16, 2024 | uk.investing.com

Earnings call: Aadi Bioscience sees 60% growth in FYARRO sales

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 16, 2024 | finance.yahoo.com

AADI Apr 2024 10.000 call

March 16, 2024 | finance.yahoo.com

AADI Oct 2024 2.500 put

March 16, 2024 | finance.yahoo.com

AADI Jul 2024 2.500 put

March 15, 2024 | seekingalpha.com

Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript

March 15, 2024 | finance.yahoo.com

Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2023 Earnings Call Transcript

March 14, 2024 | benzinga.com

Aadi Bioscience Earnings Preview

March 14, 2024 | finance.yahoo.com

Aadi Bioscience Full Year 2023 Earnings: US$2.44 loss per share (vs US$2.69 loss in FY 2022)

March 14, 2024 | finance.yahoo.com

Q4 2023 Aadi Bioscience Inc Earnings Call

March 13, 2024 | markets.businessinsider.com

TD Cowen Keeps Their Buy Rating on Aadi Bioscience (AADI)

March 13, 2024 | prnewswire.com

Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update

March 12, 2024 | markets.businessinsider.com

Here's what Wall Street expects from Aadi Bioscience's earnings report

March 6, 2024 | finance.yahoo.com

Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update

March 5, 2024 | prnewswire.com

Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

March 2, 2024 | investing.com

Aadi reports durable response in PEComa treatment study

March 1, 2024 | marketwatch.com

Stocks to Watch: BioVie, Aadi Bioscience

March 1, 2024 | marketwatch.com

Aadi Bioscience Shares Rise After Data Supports Fyarro as Treatment for Malignant PEComa

March 1, 2024 | prnewswire.com

Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa

February 26, 2024 | finance.yahoo.com

Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference

See More Headlines

Receive AADI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aadi Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AADI
CUSIP: N/A
CIK: 1422142
Web: aadibio.com
Phone: (424) 473-8055
Fax: N/A
Employees: 89
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $24.67
High Stock Price Target: $36.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +1,255.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.44)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-65,760,000.00
Net Margins: -270.04%
Pretax Margin: -270.04%
Return on Equity: -52.53%
Return on Assets: -44.29%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.72
Quick Ratio: 4.48

Sales & Book Value

Annual Sales: $24.35 million
Price / Sales: 1.83
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.29 per share
Price / Book: 0.42

Miscellaneous

Outstanding Shares: 24,550,000
Free Float: 15,764,000
Market Cap: $44.68 million
Optionable: Optionable
Beta: 0.62

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Neil P. Desai Ph.D. (Age 59)
Founder, Secretary & Executive Chairman
Comp: $1.12M
Dr. Loretta M. Itri F.A.C.P. (Age 74)
M.D., Chief Medical Officer
Comp: $805.85k
Mr. David J. Lennon Ph.D. (Age 53)
President, CEO & Director
Mr. Scott M. Giacobello CPA (Age 54)
CFO, Treasurer, Investor Relations & Corporate Communications
Comp: $495.56k
Mr. Stephen M. Rodin J.D. (Age 48)
Senior VP of Legal & General Counsel
Mr. Raymond G. Steitz (Age 65)
Senior VP of Human Resources & Chief Human Resources Officer
Mr. Bryan Ball (Age 53)
Chief Quality Officer & Senior VP of Manufacturing Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AADI Stock Analysis - Frequently Asked Questions

Should I buy or sell Aadi Bioscience stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aadi Bioscience in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AADI shares.
View AADI analyst ratings or view top-rated stocks.
What is Aadi Bioscience's stock price target for 2024?: 2 equities research analysts have issued 1 year target prices for Aadi Bioscience's shares. Their AADI share price targets range from $5.00 to $36.00. On average, they expect the company's stock price to reach $24.67 in the next year. This suggests a possible upside of 1,255.3% from the stock's current price.
View analysts price targets for AADI or view top-rated stocks among Wall Street analysts.
How have AADI shares performed in 2024?: Aadi Bioscience's stock was trading at $2.02 at the start of the year. Since then, AADI shares have decreased by 9.9% and is now trading at $1.82.
View the best growth stocks for 2024 here.
Are investors shorting Aadi Bioscience?: Aadi Bioscience saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 943,100 shares, a decline of 16.5% from the March 15th total of 1,130,000 shares. Based on an average trading volume of 386,100 shares, the short-interest ratio is currently 2.4 days. Currently, 5.4% of the company's stock are short sold.
View Aadi Bioscience's Short Interest.

When is Aadi Bioscience's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our AADI earnings forecast.
How were Aadi Bioscience's earnings last quarter?: Aadi Bioscience, Inc. (NASDAQ:AADI) issued its earnings results on Wednesday, March, 13th. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.67) by $0.07. The company had revenue of $6.33 million for the quarter, compared to analyst estimates of $6.46 million. Aadi Bioscience had a negative trailing twelve-month return on equity of 52.53% and a negative net margin of 270.04%.
When did Aadi Bioscience's stock split?: Aadi Bioscience's stock reverse split on the morning of Friday, August 27th 2021. The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
How do I buy shares of Aadi Bioscience?: Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AADI) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aadi Bioscience (AADI) Stock Price, News & Analysis

Aadi Bioscience MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Aadi Bioscience Stock (NASDAQ:AADI)

AADI Stock Price History

AADI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AADI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™